SARS-CoV 2 Clinical Trial
Official title:
SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling
Since March 2020, SARS-CoV2 virus (nCoV19; COVID-19) is considered pandemic. Its high rate of spread and infection in the human population and the lack of effective and validated treatment have led the authorities of several countries to confine their populations to slow the spread of COVID-19. As part of the management of this health crisis, the screening of individuals is essential in order to isolate "infected cases". These screening tests are currently performed on nasopharyngeal swabs using RT-PCR for the detection of viral RNA. Although sensitive and specific, these tests remain relatively long (2-5 hours), expensive and the strong international demand for nucleic extraction kits and enzymes are factors limiting the implementation of widespread screening (problem of supply of swabs, molecular biology consumables). In order to prevent the risks of a shortage of screening means, we propose to develop an innovative alternative strategy, PCR-free, based on the detection of specific protein signatures in human saliva by MALDI-TOF MS profiling. MALDI-TOF MS profiling is a method used in routine diagnostics by microbiology laboratories for the identification of microorganisms. MALDI-TOF MS profiling has been successfully used to classify individuals according to their infectious status (oral pathologies) based on the analysis of their saliva, but also as a tool for the identification of respiratory viruses from cell culture supernatants. In addition, we have expertise and skills in the field of MALDI-TOF MS profiling and have implemented new strategies to improve the quality of profiles and their analysis, particularly in the context of entomological and vector identification projects. Finally, recent Chinese studies have reported that COVID-19 was detectable in saliva by RT-PCR. The main objective of this study is to develop a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Withdrawn |
NCT04386447 -
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
|
Phase 2 | |
| Terminated |
NCT04435457 -
Cardiovascular Implications of COVID-19
|
||
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
| Completed |
NCT04615936 -
Nasal Photodisinfection COVID-19 Proof of Concept Study
|
N/A | |
| Completed |
NCT04369794 -
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
|
Phase 4 | |
| Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
| Completed |
NCT04542850 -
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19
|
N/A | |
| Completed |
NCT04382040 -
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
|
Phase 2 | |
| Completed |
NCT04378582 -
Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
|
||
| Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
| Completed |
NCT04383587 -
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
|
N/A | |
| Recruiting |
NCT04402814 -
IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
|
||
| Completed |
NCT04395924 -
Maternal-foetal Transmission of SARS-Cov-2
|
||
| Completed |
NCT04374565 -
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
|
Phase 2 | |
| Completed |
NCT04425889 -
COVID-19 Antibodies Among Healthcare Workers
|
||
| Completed |
NCT04413071 -
Cardiac COVID-19 Health Care Workers
|